CRL — Clinical Research Labs
Back to catalog
CJC-1295 (No DAC) 3ml vial label
Growth HormonePurity 99.2%
Product profile

CJC-1295 (No DAC)

Modified GHRH(1-29) analogue for pulsatile GH research.

99.2%
Purity
Lyophilized
Form
-20°C
Storage
Research Use Only. Not for human or veterinary consumption, diagnostic, or therapeutic use.

What it is

CJC-1295 without DAC (also called Mod-GRF 1-29) is a tetrasubstituted GHRH(1-29) analogue used in research of pulsatile growth-hormone release.

Pathway Diagram

Mechanism of Action

CRL · MOA-01

Binds pituitary GHRH receptors with enhanced metabolic stability vs. native GHRH; short half-life preserves natural GH pulses.

  1. Step 01
    Receptor Binding

    Peptide engages target receptor with high affinity.

  2. Step 02
    Signal Cascade

    Downstream intracellular pathways activate.

  3. Step 03
    Cellular Response

    Gene expression and protein synthesis shift.

  4. Step 04
    Observed Outcome

    Measurable change in the studied biomarker.

Primary TargetsGHRH pulsatility researchGH/IGF-1 axis studiesCombination with ghrelin mimetics

Research highlights

Tetrasubstituted GHRH(1-29) (Mod-GRF 1-29) with enhanced enzymatic stability.
Short half-life preserves natural pulsatile GH release.
Synergistic with ghrelin mimetics (ipamorelin, GHRP-6) in research.
Reliable GH/IGF-1 elevation in preclinical and clinical work.

Pharmacology snapshot

3367.8 Da
Molecular weight
~30 minutes (no DAC)
Half-life
SC (research)
Route (research)

Potential research applications

GHRH pulsatility research
GH/IGF-1 axis studies
Combination with ghrelin mimetics
Pituitary signaling

Case studies

ClinicalUp to 28 days

GH/IGF-1 stimulation in humans

Cohort: Healthy adults

Phase 1 dose-escalation of CJC-1295 on GH and IGF-1 secretion.

Outcome

Dose-dependent IGF-1 elevation with preserved pulsatility in research arms.

Teichman et al., JCEM 2006;91(3):799–805
ClinicalContinuous stimulation

Preserved GH pulsatility

Cohort: Healthy adults

Investigated pulsatile vs. tonic GH output under CJC-1295 stimulation.

Outcome

Confirmed pulsatile GH release despite continuous receptor stimulation.

Ionescu & Frohman, JCEM 2006;91(12):4792–4797
Preclinical—

GH/IGF-1 axis activation review

Cohort: Multi-model synthesis

Reviewed mechanism and outcomes of CJC-1295 on the somatotropic axis.

Outcome

Consistent IGF-1 elevation across rodent and human studies.

Sackmann-Sala et al., Growth Horm IGF Res 2009;19(6):471–477
Handling Protocol

Storage Guidelines

CRL · STR-02

Lyophilized -20°C. Reconstituted: 2–8°C, 30 days.

Lyophilized
-20°C
Long-term, 24 months
Reconstituted
2–8°C
Refrigerated, 28 days
Light Exposure
Protect
Store in dark vial
Diluent
BAC Water
Sterile, 0.9% benzyl
Best practice — reconstitute with bacteriostatic water, swirl gently, do not shake.
Regulatory Notice

Research Disclaimer

CRL · REG-03
Research Use Only

Strictly for in-vitro laboratory and research investigations.

Not For Human Use

Not approved for diagnostic, therapeutic, or veterinary application.

Qualified Personnel

Handling restricted to licensed researchers and laboratory staff.

Warning — CJC-1295 (No DAC) is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.

Document · CRL-REG-03Revision 2026.06 · Clinical Research Labs
Representative Literature

Citations & References

CRL · REF-04
  1. 01
    Teichman SL, Neale A, Lawrence B, et al. · 2006
    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone
    J Clin Endocrinol Metab. 91(3):799–805.
    DOI · 10.1210/jc.2005-1536PMID · 16352683
  2. 02
    Ionescu M, Frohman LA. · 2006
    Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GHRH analog
    J Clin Endocrinol Metab. 91(12):4792–4797.
    DOI · 10.1210/jc.2006-1702PMID · 16968793
  3. 03
    Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. · 2009
    Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog
    Growth Horm IGF Res. 19(6):471–477.
    DOI · 10.1016/j.ghir.2009.04.001PMID · 19467612
References are representative of peer-reviewed literature and are provided for research context only.
Document · CRL-REF-04Revision 2026.06 · Clinical Research Labs